The high frequency of tumor-specific CD8+ T cells in the CX3CR1+ subset before and during ICI treatment is suggestive that heterogeneous tumor-infiltrating CD8+ T cells are also enriched in the CX3CR1+ subset. The gene discussed is CD8A; the disease is neoplasm.